Comparison of the effect of insulin glulisine to insulin aspart on breakfast postprandial blood glucose levels in children with type 1 diabetes mellitus on multiple daily injections

Endocrine Practice

Volumn 19, Issue 4, 2013, Pages 614-619

  Cemeroglu, Ayse ^a   Kleis, Lora ^a   Wood, Andrew ^b   Parkes, Chad ^b   Wood, Michael ^a   Davis, Alan ^c  

^a HELEN DEVOS CHILDREN S HOSPITAL   (United States)

^b SPECTRUM HEALTH   (United States)

^c Grand Rapids Medical Education Partners   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO;

ARTICLE; CHILD; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; POSTPRANDIAL STATE; PRESCHOOL CHILD; SCHOOL CHILD;

BLOOD GLUCOSE; BREAKFAST; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS; INSULIN; INSULIN ASPART; MALE; POSTPRANDIAL PERIOD;

EID: 84883387494     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP12399.OR     Document Type: Article

References (12)

1. Gandrud LM, Xing D, Kollman C, et al. The Medtronic Minimed Gold continuous glucose monitoring system: an effective means to discover hypo-and hyperglycemia in children under 7 years of age. Diabetes Technol Ther. 2007; 9:307-316.
2. Danne T, Becker RHA, Heise T, Bittner C, Frick AD, Rave K. Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. Diabetes Care. 2005;28:2100-2105.
3. Ulrich H, Snyder B, Garg SK. Combining insulins for optimal blood glucose control in type 1 and 2 diabetes: focus on insulin glulisine. Vasc Health Risk Manag. 2007; 3:245-254.
4. Rave K, Klein O, Frick AD, Becker RH. Advantage of premeal-injected insulin glulisine compared with regular human insulin in subjects with type 1 diabetes. Diabetes Care. 2006;29:1812-1817.
5. Bolli GB, Luzio S, Marzotti S, et al. Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes. Diabetes Obes Metab. 2011;13:251-257.
6. Arnolds S, Rave K, Hövelmann U, Fischer A, Sert-Langeron C, Heise T. Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteers. Exp Clin Endocrinol Diabetes. 2010;118:662-664.
7. Becker RH, Frick AD, Burger F, Potgieter JH, Scholtz H. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects. Exp Clin Endocrinol Diabetes. 2005;113:435-443.
8. Becker RH. Insulin glulisine complementing basal insulins: a review of structure and activity. Diabetes Technol Ther. 2007;9:109-121.
9. Philotheou A, Arslanian S, Blatniczky L, Peterkova V, Souhami E, Danne T. Comparable efficacy and safety of insulin glulisine and insulin lispro when given as part of a Basal-bolus insulin regimen in a 26-week trial in pediatric patients with type 1 diabetes. Diabetes Technol Ther. 2011; 13:327-334.
10. Heise T, Nosek L, Spitzer H, Heinemann L, Niemoller E, Frick AD, et al. Insulin glulisine: a faster onset of action compared with insulin lispro. Diabetes Obes Metab. 2007; 9:746-753.
11. van Bon AC, Bode BW, Sert-Langeron C, DeVries JH, Charpentier G. Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial. Diabetes Technol Ther. 2011; 13:607-614.
12. Solnica B, Naskalski JW, Sieradzki J. Analytical performance of glucometers used for routine glucose self-monitoring of diabetic patients. Clin Chim Acta. 2003;331:29-35.